AML cell lines were treated with Vemurafenib, GW5074, and AZ628 (which are BRAF, RAF1, and dual BRAF/RAF1 inhibitors, respectively) alone or in combination with Sorafenib. Here, RAF1 is linked to acute myeloid leukemia.